Indianapolis-based Eli Lilly and Co. announced today that a clinical trial showed lung cancer patients treated with Lilly
drug Alimta lived about three months longer than those who received the best available care.
The Greater Indianapolis Chamber of Commerce announced its support for construction of a new Wishard Hospital and promised
to take a leadership position to help hospital leaders win voter approval for the project.
Medical equipment supplier Hill-Rom Holdings Inc. said yesterday it has begun a chief executive search to plan for the retirement
of current CEO Peter Soderberg.
The drugmaker has successfully moved experimental drugs into position to win approval by regulators. But only once in the
last four years has a new drug actually made it to market—the industry’s equivalent of getting
across the goal line.
Employees at five different companies collectively lost 805 pounds over six weeks this summer. They also
raised $805 for Big Brothers/Big Sisters of Central Indiana.
Migraines cost American employers $20 billion a year in decreased worker productivity. Such
a frequent and uncured disease stands as a huge business opportunity for the health care industry, including locally based pharmaceutical giant Eli Lilly and Co.
The launch of the orthopedics not-for-profit OrthoWorx is quite an accomplishment in Warsaw, where some of the world’s
biggest companies fight tooth-and-nail.
The Westfield City Council passed a smoking ban 7-0 last night that will prohibit smoking in most public places, including
outdoor arenas, stadiums and amphitheaters.
Since John Lechleiter was named CEO 18 months ago, he’s bet that Eli Lilly and Co. could face down its looming patent challenges
by launching innovative new medicines. Today’s announcement of 5,500 job cuts by the end of 2011 and a restructuring of the
company’s business units ups the ante on that bet, while indicating that it isn’t working yet.
Eli Lilly and Co. will cut 5,500 jobs by the end of 2011 as it tries to cut $1 billion in expenses before it loses revenue
from its bestselling drug, Zyprexa. Lilly CEO John Lechleiter said he did not know how many of those cuts would occur in central
Indiana. But with
13,600 employees working in the Indianapolis area, he acknowledged the largest chunk of reductions likely would come here.
Take the money while it’s there. That’s what a handful of insiders at WellPoint Inc. decided in
the past month as they sold off nearly 150,000 company shares for gains of more than $3 million.
Eli Lilly and Co. and its peers might be back in Congress’ sights as lawmakers hunt for more ways to cut health care
costs. A new study in the influential Health Affairs journal concludes that European drugmakers operating
in markets with pharmaceutical price controls have produced proportionally more innovations than their U.S. counterparts.
If President Barack Obama gets what he wants in his health care plan — covering all Americans and barring insurers from
denying coverage — some analysts say individuals could wind up paying higher premiums.
Indiana Gov. Mitch Daniels outlined his concerns about some of the health care proposals being debated in Congress in a letter
sent to the state’s congressional delegation and released by his office yesterday.
If Congress implements a new system of health insurance exchanges across the country, Indianapolis benefits broker Joe
Guzman is confident he and his peers would take a hit.
Nine months after being suspended as a contractor for the federal Medicare program, WellPoint Inc. is back in the game.
Indianapolis-based FAST Diagnostics, a developer of a method to quickly measure kidney function, announced today that it has
received $1 million in federal funding.
With job growth surging in Warsaw’s orthopedic cluster, the life sciences development group BioCrossroads Inc. set out to…
Eli Lilly and Co. paid doctors in South Carolina for participating in a speakers’ program in exchange for prescribing the
antipsychotic Zyprexa, according to notes by Lilly sales representatives reviewed by Bloomberg News.
Heartland Sweeteners LLC is now a top maker of private-label alternatives to Splenda. The company also
markets its own products directly to consumers.
